ArticleFrontiers in surgery2025
Outcomes after therapeutic SBE-ERCP for choledochojejunal/hepaticojejunal anastomotic stenosis after bile duct injury.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Choledochojejunal/hepaticojejunal anastomotic stenosis (CJS/HJS) is significant clinical problem associated with decreased survival postsurgery. Endoscopic retrograde cholangiopancreatography (ERCP) using single-balloon enteroscopy (SBE) is the first-line management strategy for such conditions. However, studies on the risk factors and outcomes of endoscopic management strategies for CJS/HJS in biliary duct injury (BDI) are extremely limited. Methods: We conducted a retrospective review of patients with symptomatic BDI who underwent choledochojejunal/hepaticojejunal Roux-en-Y anastomosis between April 2009 and April 2019. The primary endpoint was CJS/HJS recurrence. The secondary endpoint was early (i.e., emergent or unplanned) repeat SBE-ERCP (ER-SBE-ERCP). We also evaluated the details of initial therapy, complications, and treatment for CJS or HJS recurrence. Results: From April 2009 to April 2019, 112 patients were treated, and 45 (40.2%) BDI patients developed CJS/HJS. Operation type ( Conclusions: Initial balloon dilation is associated with a decreased risk of CJS/HJS recurrence. ER-SBE-ERCP is more commonly performed in patients with severe anastomotic lesions or higher baseline risks for recurrence, which may contribute to the higher observed recurrence rates of CJS/HJS in this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.